Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives
- PMID: 26084656
- DOI: 10.1038/jhh.2015.61
Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives
Abstract
Little is known about the impact of treatment-resistant hypertension (TRH) on health-related quality of life (HrQoL). We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011. Cohorts compared were adults with aTRH (⩾2 unique fills from ⩾4 antihypertensive classes during a year) versus non-resistant hypertension (those with hypertension not meeting the aTRH definition). Key outcomes were cohort differences in SF-12v2 physical component summary (PCS) and mental component summary (MCS) scores and disease-state utility using the SF-6D. Of 57 150 adults with hypertension, 2501 (4.4%) met criteria for aTRH. Persons with aTRH, compared with non-resistant hypertension, were older (mean, 68 vs 61 years), had a higher BMI (30.9 vs 29.7 kg m(-)(2)) and were more likely to be Black (20% vs 14%), but less likely to be female (46% vs 54%). Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4). In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension. In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension. The multivariable-adjusted reduction in physical functioning was similar in magnitude to previous observations comparing hypertension with no hypertension.
Similar articles
-
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4. Hypertension. 2014. PMID: 25259745 Clinical Trial.
-
Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.Hypertension. 2015 Nov;66(5):998-1005. doi: 10.1161/HYPERTENSIONAHA.115.05694. Epub 2015 Sep 8. Hypertension. 2015. PMID: 26351024
-
Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.Hypertension. 2016 Feb;67(2):387-96. doi: 10.1161/HYPERTENSIONAHA.115.06487. Epub 2015 Dec 28. Hypertension. 2016. PMID: 26711738 Free PMC article.
-
Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?Adv Chronic Kidney Dis. 2014 Nov;21(6):489-99. doi: 10.1053/j.ackd.2014.08.006. Epub 2014 Oct 24. Adv Chronic Kidney Dis. 2014. PMID: 25443574 Review.
-
[Effect of antihypertensive therapy on quality of life].Kardiologiia. 2003;43(3):99-102. Kardiologiia. 2003. PMID: 12913990 Review. Russian. No abstract available.
Cited by
-
Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.Future Cardiol. 2024;20(9):435-445. doi: 10.1080/14796678.2024.2367390. Epub 2024 Jul 2. Future Cardiol. 2024. PMID: 38953510 Review.
-
Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease.Am J Hypertens. 2024 May 15;37(6):438-446. doi: 10.1093/ajh/hpae020. Am J Hypertens. 2024. PMID: 38436491 Free PMC article.
-
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.J Clin Hypertens (Greenwich). 2023 Aug;25(8):737-747. doi: 10.1111/jch.14701. Epub 2023 Jul 17. J Clin Hypertens (Greenwich). 2023. PMID: 37461262 Free PMC article.
-
Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension.Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e005979. doi: 10.1161/CIRCOUTCOMES.119.005979. Epub 2020 Feb 3. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32008359 Free PMC article. No abstract available.
-
Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.J Clin Hypertens (Greenwich). 2019 Jun;21(6):825-834. doi: 10.1111/jch.13550. Epub 2019 May 7. J Clin Hypertens (Greenwich). 2019. PMID: 31066177 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
